Evidence map›Paper›PMID 27713618›Full record

ArticleDrug design, development and therapy2016

Radiolabeled tirofiban - a potential radiopharmaceutical for detection of deep venous thrombosis.

Marija Darkovska-Serafimovska, Emilija Janevik-Ivanovska, Icko Djorgoski, Zorica Arsova-Sarafinovska, Milka Zdravkovska, Trajan Balkanov, Nenad Ugresic

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Marija Darkovska-SerafimovskaDepartment of Pharmacy, Faculty of Medical Sciences, Goce Delcev University, Stip; Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Emilija Janevik-IvanovskaDepartment of Pharmacy, Faculty of Medical Sciences, Goce Delcev University, Stip.
Icko DjorgoskiDepartment of Physiology, Faculty of Natural Sciences and Mathematics, Ss Cyril and Methodius University in Skopje.
Zorica Arsova-SarafinovskaDepartment of Pharmacy, Faculty of Medical Sciences, Goce Delcev University, Stip; Department of Quality Control of Medicines, Institute for Public Health of the Republic of Macedonia.
Milka ZdravkovskaDepartment of Pharmacy, Faculty of Medical Sciences, Goce Delcev University, Stip.
Trajan BalkanovDepartment of Pharmacology and Toxicology, Faculty of Medicine, Ss Cyril and Methodius University in Skopje, Skopje, Republic of Macedonia.
Nenad UgresicDepartment of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Goce Delcev University · MKSaints Cyril and Methodius University of Skopje · MKInstitute of public health of Republic of Macedonia · MKUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe aim of this study was to investigate the possibility of using

methodsThe ability of in vitro tirofiban to inhibit adenosine 5'-diphosphate (ADP)-induced platelet aggregation was evaluated using optical aggregometer. Binding of

resultsTirofiban in vitro inhibits ADP-induced aggregation of human platelets in a dose- and concentration-dependent manner (10 nM to 2 μM), but only if it is added before ADP and not after ADP.

conclusion

Indexed as

Adenosine DiphosphateAnimalsHumansMalePlatelet AggregationPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRadiopharmaceuticalsRatsRats, WistarTirofibanTyrosineVenous ThrombosisAdenosine DiphosphatePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRadiopharmaceuticalsTirofibanTyrosine99mtechnetiumdeep venous thrombosistirofibanvisualization

Identifiers

PMID27713618
PMCPMC5044985
OpenAlexW2524004701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.